Most deadly drug-resistant infections in poorer countries go untreated, study shows

Most deadly drug-resistant infections in poorer countries go untreated, study shows

A new modelling study reveals that only 7% of carbapenem-resistant Gram-negative (CRGN) bacterial infections in eight LMICs receive effective antibiotic treatment. This stark undertreatment poses a major threat in the global fight against antimicrobial resistance (AMR).

Model Evidences Wide Treatment Gap for Carbapenem-Resistant Gram-Negative Infections

An "alarmingly" wide treatment gap for antimicrobial-resistant infections in under resourced countries is attributed to multiple factors including barriers to access.